In recent times, there has been a considerable increase in the use of aortic bioprostheses
(vs. mechanical prostheses) for treating aortic valve disease, and this tendency is likely to …

Mechanical valves used for aortic valve replacement (AVR) continue to be associated with
bleeding risks because of anticoagulation therapy, while bioprosthetic valves are at risk of …

The “Guidelines on the Management of Valvular Heart Disease” were initially published as
the “Guidelines on Non-pharmacological Treatment of Valvular Heart Disease” in 2002 …

Transcatheter aortic valve implantation (TAVI) has become the standard of care for
inoperable patients, and the preferred treatment option for high-risk patients with severe …

A large amount of evidence supports the widespread use of transcatheter aortic valve
replacement (TAVR) among patients who are at low to intermediate risk for surgery …

Every year, thousands of aortic valve replacements must take place due to valve diseases.
Tissue-engineered heart valves represent promising valve substitutes with remodeling …

The main limitation of bioprosthetic valves is their limited durability, which exposes the
patient to the risk of aortic valve reintervention. Transcatheter aortic valve implantation …

Mitral transcatheter therapies represent the treatment of choice for all patients deemed
unsuitable for cardiac surgery. So far, the largest clinical experience has been limited to …

Background Bioprosthetic heart valves (BHVs), fabricated from glutaraldehyde‐pretreated
bovine pericardium or porcine aortic valves, are widely used for the surgical or interventional …

Background Porcine and pericardial valves exhibited similar freedom from structural valve
deterioration after aortic valve replacement. Limited data exist regarding their durability at …